Technology
Dual-Action Car-T Therapy:
Targeting both the tumor and its immunosuppressive microenvironment
• Direct tumor cell killing via EGFRvIII targeting
• Secretion of CD47-blocking SGRP to overcome immune evasion
• Reprogramming of tumor-associated macrophages into tumor-fighting cells
Our unique Dual-action CAR-T therapy for GBM
Dual-mechanism overcomes immunesuppression and heterogeneity enabling durable anti-tumor immunity
Short description
Conventional CAR-T therapies have shown remarkable success in blood cancers but face key limitations in solid tumors due to immunosuppression and antigen escape.
GlioCART addresses these barriers through a dual-action approach targeting both the tumor and its microenvironment.
